Key result
Adiponectin and extracellular vesicles show combined therapeutic potential for age-related diseases via systemic inter-organ communication.
Why the study?
With population aging driving chronic diseases and straining healthcare systems, developing improved therapies such as adiponectin and extracellular vesicles is essential to enhance healthspan.
Answers are grounded in this paper and cite their sources.
Adiponectin and extracellular vesicles show potential as diagnostic and therapeutic tools for improving healthspan and treating age-related diseases.
The gradual decline in physiological functions that comes with aging contributes to a range of chronic diseases, such as Alzheimer's, type 2 diabetes, heart failure, and osteoarthritis. Significant advancements in human longevity due to socioeconomic development have resulted in a foreseeable and substantial strain on the global healthcare system. In fact, there is now a shift in research focus towards enhancing healthspan. As a result, the development of improved therapies for various chronic diseases is essential to enhance healthspan in the aging population. Adiponectin, mainly produced in adipose tissue, is found at elevated levels in the blood of healthy centenarians. In contrast, lower circulating levels of adiponectin are inversely associated with the occurrence and severity of several age-related complications. Adiponectin plays a crucial role in promoting beneficial effects on key biological processes associated with aging-related diseases, contributing to improved healthspan and lifespan in preclinical models. In recent years, extracellular vesicles (EVs) have garnered significant research interest due to their crucial role in both local paracrine signaling and systemic inter-organ communication. They are now widely recognized for their potential as valuable diagnostic and therapeutic tools. In this review, we summarize current knowledge on the pathophysiological roles of adiponectin and EVs in aging, emphasizing their combined therapeutic potential in age-related diseases. Additionally, we explore the emerging evidence of crosstalk between adiponectin and EVs, underscoring their potential for developing improved strategies to promote healthy aging and longevity. • Adiponectin is found at elevated levels in the blood of healthy centenarians and lower circulating levels of adiponectin are inversely associated with the occurrence and severity of several age-related complications. • Adiponectin plays a crucial role in promoting beneficial effects on key biological processes associated with aging-related diseases, contributing to improved healthspan and lifespan in preclinical models. • Extracellular vesicles (EVs) act as important paracrine and endocrine communicators and regulate healthspan. • Both adiponectin and EV are recognized for their potential as valuable diagnostic and therapeutic tools. • We summarize current knowledge on the pathophysiological roles of adiponectin and EV in ageing-associated diseases and emphasize their combined therapeutic potential in modualting healthspan.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2025) conducted a review in Aging and age-related diseases. Adiponectin and extracellular vesicles was evaluated. Adiponectin and extracellular vesicles demonstrate combined therapeutic potential for modulating healthspan and treating age-related diseases through their roles in systemic inter-organ communication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: